Hybrid was selected by Abbott Laboratories and their agency Vox Medica, Inc. to create a MOA animation centered on Abbott’s development of a new cancer-specific, oral selective endothelin-A receptor
antagonist (SERA™).
This 6-minute animation was produced by Hybrid to help expand viewers’ understanding of:
• Hormone-refractory prostate cancer
• The Endothelin Axis
• The impact of this new receptor
antagonist on the endothelin-A pathway
The project was produced and set up in a way that enabled our clients to select scenes from the MOA and re-render them for use
in their large-scale booth display panels
at ASCO.
This sequence on bone metastasis is a segment from the animation.
